Fig. 5

Effects of LETX-VI on VMAT2 and DAT. A: Effect of LETX-VI on the contents of glycosylated vesicular monoamine transporter 2 (g-VMAT2) and non-glycolslyated vesicular monoamine transporter 2 (non-g-VMAT2). B: Effect of LETX-VI on the content of dopamine transporter (DAT). C: Effect of LETX-VI on the content of dopamine transporter phosphorylated at T53 (p-DAT). D: Content of DAT detected with fluorescent-labeled antibody before LETX-VI treatment. E: Content of DAT detected with fluorescent-labeled antibody after 1 µM LETX-VI treatment for 24 h. F: Content of DAT detected with fluorescent-labeled antibody after 2 µM LETX-VI treatment for 24 h. The 4× and 10× immunofluorescence images for DAT analysis were shown in the the Additional file 2: Supplementary 4× and 10× immunofluorescence and Nissl staining images. *P < 0.05, ** P < 0.01. n ≥ 3